The DOI matches its Crossref record; 15 of the 23 references it cites were found in a registry or an index, and 8 are not checked yet.
Gene Expression Alterations in Prostate Cancer Predicting Tumor Aggression and Preceding Development of Malignancy
Abstract
Purpose: The incidence of prostate cancer is frequent, occurring in almost one-third of men older than 45 years. Only a fraction of the cases reach the stages displaying clinical significance. Despite the advances in our understanding of prostate carcinogenesis and disease progression, our knowledge of this disease is still fragmented. Identification of the genes and patterns of gene expression will provide a more cohesive picture of prostate cancer biology. Patients and Methods: In this study, we performed a comprehensive gene expression analysis on 152 human samples including prostate cancer tissues, prostate tissues adjacent to tumor, and organ donor prostate tissues, obtained from men of various ages, using the Affymetrix (Santa Clara, CA) U95a, U95b, and U95c chip sets (37,777 genes and expression sequence tags). Results: Our results confirm an alteration of gene expression in prostate cancer when comparing with nontumor adjacent prostate tissues. However, our study also indicates that the gene expression pattern in tissues adjacent to cancer is so substantially altered that it resembles a cancer field effect. Conclusion: We also found that gene expression patterns can be used to predict the aggressiveness of prostate cancer using a novel model.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
Fundamentals of Biostatistics.
(1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-70-4-873 · Cited by 4,575
Classical and Modern Regression With Applications.
Steinhorst, R. K., & Myers, R. H. (1988) · Journal of the American Statistical Association · doi:10.2307/2288958 · Cited by 3,690
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
Gene expression correlates of clinical prostate cancer behavior
Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00030-2 · Cited by 2,512
Delineation of prognostic biomarkers in prostate cancer
Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M. (2001) · Nature · doi:10.1038/35090585 · Cited by 1,673
Welsh, J. B., Sapinoso, L. M., Su, A. I., Kern, S. G., Wang‐Rodriguez, J., Moskaluk, C. A., Frierson, H. F., & Hampton, G. M. (2001) · PubMed · Cited by 856
Latulippe, É., Satagopan, J. M., Smith, A., Scher, H. I., Scardino, P. T., Reuter, V. E., & Gerald, W. L. (2002) · PubMed · Cited by 518
Cited by
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
The landscape of long noncoding RNAs in the human transcriptome
Iyer, M. K., Niknafs, Y. S., Malik, R., Singhal, U., Sahu, A., Hosono, Y., Barrette, T. R., Prensner, J. R., Evans, J. R., Zhao, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3192 · Cited by 2,738
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
Xu, K., Wu, Z. J., Groner, A. C., He, H. H., Cai, C., Lis, R. T., Wu, X., Stack, E. C., Loda, M., Liu, T., et al. (2012) · Science · doi:10.1126/science.1227604 · Cited by 875
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer
Tomlins, S. A., Laxman, B., Dhanasekaran, S. M., Helgeson, B. E., Cao, X., Morris, D. S., Menon, A., Jing, X., Cao, Q., Han, B., et al. (2007) · Nature · doi:10.1038/nature06024 · Cited by 844
Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA
Wang, D., Garcia-Bassets, I., Benner, C., Li, W., Su, X., Zhou, Y., Qiu, J., Liu, W., Kaikkonen, M. U., Ohgi, K. A., et al. (2011) · Nature · doi:10.1038/nature10006 · Cited by 827
Varambally, S., Yu, J., Laxman, B., Rhodes, D. R., Mehra, R., Tomlins, S. A., Shah, R. B., Chandran, U., Monzon, F. A., Becich, M. J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.001 · Cited by 800
Self-citationCuzick, J., Swanson, G. P., Fisher, G., Brothman, A. R., Berney, D. M., Reid, J. E., Mesher, D., Speights, V., Stankiewicz, E., Foster, C. S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70295-3 · Cited by 792
The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3
Cloos, P. A. C., Christensen, J., Agger, K., Maiolica, A., Rappsilber, J., Antal, T., Hansen, K. H., & Helin, K. (2006) · Nature · doi:10.1038/nature04837 · Cited by 736
ConsensusPathDB: toward a more complete picture of cell biology
Kamburov, A., Pentchev, K., Galicka, H., Wierling, C., Lehrach, H., & Herwig, R. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1156 · Cited by 671
Prensner, J. R., Iyer, M. K., Sahu, A., Asangani, I. A., Cao, Q., Patel, L., Vergara, I. A., Davicioni, E., Erho, N., Ghadessi, M., et al. (2013) · Nature Genetics · doi:10.1038/ng.2771 · Cited by 669
The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer
Chakravarty, D., Sboner, A., Nair, S. S., Giannopoulou, E., Li, R., Hennig, S., Mosquera, J. M., Pauwels, J., Park, K., Kossai, M., et al. (2014) · Nature Communications · doi:10.1038/ncomms6383 · Cited by 621
Comprehensive analysis of normal adjacent to tumor transcriptomes
Aran, D., Camarda, R., Odegaard, J., Paik, H., Oskotsky, B., Krings, G., Goga, A., Sirota, M., & Butte, A. J. (2017) · Nature Communications · doi:10.1038/s41467-017-01027-z · Cited by 617
Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy
Shalapour, S., Font-Burgada, J., Di Caro, G., Zhong, Z., Sanchez-Lopez, E., Dhar, D., Willimsky, G., Ammirante, M., Strasner, A., Hansel, D. E., et al. (2015) · Nature · doi:10.1038/nature14395 · Cited by 611
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression
Ding, Z., Wu, C.-J., Chu, G. C., Xiao, Y., Ho, D., Zhang, J., Perry, S. R., Labrot, E. S., Wu, X., Lis, R., et al. (2011) · Nature · doi:10.1038/nature09677 · Cited by 515
Chandran, U. R., Ma, C., Dhir, R., Bisceglia, M., Lyons-Weiler, M., Liang, W., Michalopoulos, G., Becich, M., & Monzon, F. A. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-64 · Cited by 495
Self-citationp62 Is a Key Regulator of Nutrient Sensing in the mTORC1 Pathway
Duran, A., Amanchy, R., Linares, J. F., Joshi, J., Abu-Baker, S., Porollo, A., Hansen, M., Moscat, J., & Diaz-Meco, M. T. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.06.038 · Cited by 472
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis
Gurel, B., Iwata, T., M Koh, C., Jenkins, R. B., Lan, F., Van Dang, C., Hicks, J. L., Morgan, J., Cornish, T. C., Sutcliffe, S., et al. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.111 · Cited by 441
Self-citationDi Vizio, D., Morello, M., Dudley, A. C., Schow, P. W., Adam, R. M., Morley, S., Mulholland, D., Rotinen, M., Hager, M. H., Insabato, L., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.07.030 · Cited by 422
Sharma, N. L., Massie, C. E., Ramos-Montoya, A., Zecchini, V., Scott, H. E., Lamb, A. D., MacArthur, S., Stark, R., Warren, A. Y., Mills, I. G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.010 · Cited by 405
Targeting the androgen receptor pathway in prostate cancer
Chen, Y., Sawyers, C. L., & Scher, H. I. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.07.005 · Cited by 389
Gal-Yam, E. N., Egger, G., Iniguez, L., Holster, H., Einarsson, S., Zhang, X., Lin, J. C., Liang, G., Jones, P. A., & Tanay, A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806437105 · Cited by 380
Copy number alteration burden predicts prostate cancer relapse
Hieronymus, H., Schultz, N., Gopalan, A., Carver, B. S., Chang, M. T., Xiao, Y., Heguy, A., Huberman, K., Bernstein, M., Assel, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411446111 · Cited by 364
A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer Outcome
Yu, J., Yu, J., Rhodes, D. R., Tomlins, S. A., Cao, X., Chen, G., Mehra, R., Wang, X., Ghosh, D., Shah, R. B., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2498 · Cited by 348
Up-Regulation of Dicer, a Component of the MicroRNA Machinery, in Prostate Adenocarcinoma
Chiosea, S., Jelezcova, E., Chandran, U., Acquafondata, M., McHale, T., Sobol, R. W., & Dhir, R. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.060480 · Cited by 347
Self-citationHIF-1 regulation: not so easy come, easy go
Koh, M. Y., Spivak-Kroizman, T. R., & Powis, G. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.08.002 · Cited by 339
Chen, Y., Clegg, N. J., & Scher, H. I. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70229-3 · Cited by 324
The Role of SPINK1 in ETS Rearrangement-Negative Prostate Cancers
Tomlins, S. A., Rhodes, D. R., Yu, J., Varambally, S., Mehra, R., Perner, S., Demichelis, F., Helgeson, B. E., Laxman, B., Morris, D. S., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.04.016 · Cited by 314
Wang, Z. A., Mitrofanova, A., Bergren, S. K., Abate-Shen, C., Cardiff, R. D., Califano, A., & Shen, M. M. (2013) · Nature Cell Biology · doi:10.1038/ncb2697 · Cited by 304
Koh, C. M., Bieberich, C. J., Dang, C. V., Nelson, W. G., Yegnasubramanian, S., & De Marzo, A. M. (2010) · Genes & Cancer · doi:10.1177/1947601910379132 · Cited by 296
Clinical implications and utility of field cancerization
Dakubo, G. D., Jakupciak, J. P., Birch-Machin, M. A., & Parr, R. L. (2007) · Cancer Cell International · doi:10.1186/1475-2867-7-2 · Cited by 294
Lynch, T. P., Ferrer, C. M., Jackson, S. R., Shahriari, K. S., Vosseller, K., & Reginato, M. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.302547 · Cited by 286
DNA Damage Response Genes and the Development of Cancer Metastasis
Broustas, C. G., & Lieberman, H. B. (2014) · Radiation Research · doi:10.1667/rr13515.1 · Cited by 275
Chmelar, R., Buchanan, G., Need, E. F., Tilley, W., & Greenberg, N. M. (2007) · International Journal of Cancer · doi:10.1002/ijc.22365 · Cited by 255
IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling
Sheng, X., Nenseth, H. Z., Qu, S., Kuzu, O. F., Frahnow, T., Simon, L., Greene, S., Zeng, Q., Fazli, L., Rennie, P. S., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08152-3 · Cited by 228
Chen, C., Mahalingam, D., Osmulski, P., Jadhav, R. R., Wang, C., Leach, R. J., Chang, T., Weitman, S. D., Kumar, A. P., Sun, L., et al. (2013) · The Prostate · doi:10.1002/pros.22625 · Cited by 239
Yu, Y. P., Yu, G., Tseng, G., Cieply, K., Nelson, J., Defrances, M., Zarnegar, R., Michalopoulos, G., & Luo, J.-H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0648 · Cited by 231
Self-citationHennessy, B. T., Lu, Y., Gonzalez-Angulo, A. M., Carey, M. S., Myhre, S., Ju, Z., Davies, M. A., Liu, W., Coombes, K., Meric-Bernstam, F., et al. (2010) · Clinical Proteomics · doi:10.1007/s12014-010-9055-y · Cited by 241
Micalizzi, D. S., Christensen, K. L., Jedlicka, P., Coletta, R. D., Barón, A. E., Harrell, J. C., Horwitz, K. B., Billheimer, D., Heichman, K. A., Welm, A. L., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37815 · Cited by 232
Yu, J., Cao, Q., Mehra, R., Laxman, B., Yu, J., Tomlins, S. A., Creighton, C. J., Dhanasekaran, S. M., Shen, R., Chen, G., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.016 · Cited by 223
Global levels of histone modifications predict prostate cancer recurrence
Ellinger, J., Kahl, P., von der Gathen, J., Rogenhofer, S., Heukamp, L. C., Gütgemann, I., Walter, B., Hofstädter, F., Büttner, R., Müller, S. C., et al. (2010) · The Prostate · doi:10.1002/pros.21038 · Cited by 220
CYP17 inhibitors for prostate cancer therapy
Vasaitis, T. S., Bruno, R. D., & Njar, V. C. O. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.11.005 · Cited by 215
Wang, L., Heidt, D. G., Lee, C. J., Yang, H., Logsdon, C. D., Zhang, L., Fearon, E. R., Ljungman, M., & Simeone, D. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.018 · Cited by 214
Ding, Z., Wu, C.-J., Jaskelioff, M., Ivanova, E., Kost-Alimova, M., Protopopov, A., Chu, G. C., Wang, G., Lu, X., Labrot, E. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.039 · Cited by 220
“…tumors from six prostate cancer cohorts on Oncomine (Lapointe et al., 2004; LaTulippe et al., 2002; Vanaja et al., 2003; Varambally et al., 2005; Yu et al., 2004; Holzbeierlein et al., 2004) to define the subset of genes exhibiting a progression-correlated expression pattern in human; namely,…”
Targeting the MLL complex in castration-resistant prostate cancer
Malik, R., Khan, A. P., Asangani, I. A., Cieślik, M., Prensner, J. R., Wang, X., Iyer, M. K., Jiang, X., Borkin, D., Escara-Wilke, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3830 · Cited by 210
Molecular sampling of prostate cancer: a dilemma for predicting disease progression
Sboner, A., Demichelis, F., Calza, S., Pawitan, Y., Setlur, S. R., Hoshida, Y., Perner, S., Adami, H.-O., Fall, K., Mucci, L. A., et al. (2010) · BMC Medical Genomics · doi:10.1186/1755-8794-3-8 · Cited by 218
Role of SRC-1 in the Promotion of Prostate Cancer Cell Growth and Tumor Progression
Agoulnik, I. U., Vaid, A., Bingman, W. E., Erdeme, H., Frolov, A., Smith, C. L., Ayala, G., Ittmann, M. M., & Weigel, N. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3541 · Cited by 202
MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer
Suh, S. O., Chen, Y., Zaman, M. S., Hirata, H., Yamamura, S., Shahryari, V., Liu, J., Tabatabai, Z. L., Kakar, S., Deng, G., et al. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr036 · Cited by 206
Brennan, S. E., Kuwano, Y., Alkharouf, N., Blackshear, P. J., Gorospe, M., & Wilson, G. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4238 · Cited by 205
A basal stem cell signature identifies aggressive prostate cancer phenotypes
Smith, B. A., Sokolov, A., Uzunangelov, V., Baertsch, R., Newton, Y., Graim, K., Mathis, C., Cheng, D., Stuart, J. M., & Witte, O. N. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518007112 · Cited by 193
The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis
Frohlich, D. A., McCabe, M. T., Arnold, R. S., & Day, M. L. (2008) · Oncogene · doi:10.1038/onc.2008.79 · Cited by 192
Nadiminty, N., Tummala, R., Lou, W., Zhu, Y., Zhang, J., Chen, X., deVere White, R. W., Kung, H.-J., Evans, C. P., & Gao, A. C. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.278705 · Cited by 186
Arredouani, M. S., Lu, B., Bhasin, M., Eljanne, M., Yue, W., Mosquera, J.-M., Bubley, G. J., Li, V., Rubin, M. A., Libermann, T. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0911 · Cited by 184
Li, Y., Kuscu, C., Banach, A., Zhang, Q., Pulkoski-Gross, A., Kim, D., Liu, J., Roth, E., Li, E., Shroyer, K. R., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2875 · Cited by 183
Challenges in Clinical Prostate Cancer: Role of Imaging
Kelloff, G. J., Choyke, P., & Coffey, D. S. (2009) · American Journal of Roentgenology · doi:10.2214/ajr.09.2579 · Cited by 184
Coolen, M. W., Stirzaker, C., Song, J. Z., Statham, A. L., Kassir, Z., Moreno, C. S., Young, A. N., Varma, V., Speed, T. P., Cowley, M., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2023 · Cited by 183
Turley, R. S., Finger, E. C., Hempel, N., How, T., Fields, T. A., & Blobe, G. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3117 · Cited by 181
Nakagawa, T., Kollmeyer, T. M., Morlan, B. W., Anderson, S. K., Bergstralh, E. J., Davis, B. J., Asmann, Y. W., Klee, G. G., Ballman, K. V., & Jenkins, R. B. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002318 · Cited by 179
Cheng, Q., Butler, W., Zhou, Y., Zhang, H., Tang, L., Perkinson, K., Chen, X., Jiang, X. “., McCall, S. J., Inman, B. A., et al. (2022) · European Urology · doi:10.1016/j.eururo.2021.12.039 · Cited by 178
Wang, Q., Tiffen, J., Bailey, C. G., Lehman, M. L., Ritchie, W., Fazli, L., Metierre, C., Feng, Y. (., Li, E., Gleave, M., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt241 · Cited by 176
COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis
Qin, J., Wu, S.-P., Creighton, C. J., Dai, F., Xie, X., Cheng, C.-M., Frolov, A., Ayala, G., Lin, X., Feng, X.-H., et al. (2013) · Nature · doi:10.1038/nature11674 · Cited by 175
McCoy, E. L., Iwanaga, R., Jedlicka, P., Abbey, N.-S., Chodosh, L. A., Heichman, K. A., Welm, A. L., & Ford, H. L. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37691 · Cited by 172
Taniguchi, C. M., Winnay, J., Kondo, T., Bronson, R. T., Guimaraes, A. R., Alemán, J. O., Luo, J., Stephanopoulos, G., Weissleder, R., Cantley, L. C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3399 · Cited by 166
Self-citationKomura, K., Jeong, S. H., Hinohara, K., Qu, F., Wang, X., Hiraki, M., Azuma, H., Lee, G.-S. M., Kantoff, P. W., & Sweeney, C. J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600420113 · Cited by 164
Wang, Q., Bailey, C. G., Ng, C., Tiffen, J., Thoeng, A., Minhas, V., Lehman, M. L., Hendy, S. C., Buchanan, G., Nelson, C. C., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1821 · Cited by 165
Chronotherapy and the molecular clock: Clinical implications in oncology☆
Innominato, P. F., Lévi, F. A., & Bjarnason, G. A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.06.002 · Cited by 164
Chandran, U. R., Dhir, R., Ma, C., Michalopoulos, G., Becich, M., & Gilbertson, J. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-45 · Cited by 160
Self-citationA transcriptional repressor co‐regulatory network governing androgen response in prostate cancers
Chng, K. R., Chang, C. W., Tan, S. K., Yang, C., Hong, S. Z., Sng, N. Y. W., & Cheung, E. C. W. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.112 · Cited by 159
Ezponda, T., Popovic, R., Shah, M. Y., Martinez-Garcia, E., Zheng, Y., Min, D.-J., Will, C., Neri, A., Kelleher, N. L., Yu, J., et al. (2013) · Oncogene · doi:10.1038/onc.2012.297 · Cited by 158
Complex patterns of ETS gene alteration arise during cancer development in the human prostate
Clark, J., Attard, G., Jhavar, S. G., Flohr, P., Reid, A. H. M., Bono, J. S. D., Eeles, R. A., Scardino, P. T., Cuzick, J. M., Fisher, G., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210843 · Cited by 156
ICGC Project on Early Onset Prostate Cancer, Gu, L., Frommel, S. C., Oakes, C. C., Simon, R., Grupp, K., Gerig, C. Y., Bär, D., Robinson, M. D., Baer, C. R., et al. (2014) · Nature Genetics · doi:10.1038/ng.3165 · Cited by 155
Androgen Receptor-Independent Function of FoxA1 in Prostate Cancer Metastasis
Jin, H., Zhao, J. C., Ogden, I., Bergan, R. C., & Yu, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3468 · Cited by 156
Mortensen, M. M., Høyer, S., Lynnerup, A.-S., Orntoft, T. F., Sørensen, K. D., Borre, M., & Dyrskjøt, L. (2015) · Scientific Reports · doi:10.1038/srep16018 · Cited by 152
Evidence for field cancerization of the prostate
Nonn, L., Ananthanarayanan, V., & Gann, P. H. (2009) · The Prostate · doi:10.1002/pros.20983 · Cited by 151
TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression
Fong, K.-W., Zhao, J. C., Song, B., Zheng, B., & Yu, J. (2018) · Nature Communications · doi:10.1038/s41467-018-07475-5 · Cited by 156
Cai, C., He, H. H., Gao, S., Chen, S., Yu, Z., Gao, Y., Chen, S., Chen, M. W., Zhang, J., Ahmed, M., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.11.008 · Cited by 151
Wikström, P., Marusic, J., Stattin, P. E., & Bergh, A. R. J. (2009) · The Prostate · doi:10.1002/pros.20927 · Cited by 147
Cholesterol accumulation in prostate cancer: A classic observation from a modern perspective
Krycer, J. R., & Brown, A. J. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.01.002 · Cited by 162
Frigo, D. E., Howe, M. K., Wittmann, B. M., Brunner, A. M., Cushman, I., Wang, Q., Brown, M. A., Means, A. R., & McDonnell, D. P. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2581 · Cited by 144
The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer
Kim, H., Lapointe, J., Kaygusuz, G., Ong, D. E., Li, C., van de Rijn, M., Brooks, J. D., & Pollack, J. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4562 · Cited by 147
Zhao, Y., Wang, L., Ren, S., Wang, L., Blackburn, P. R., McNulty, M. S., Gao, X., Qiao, M., Vessella, R. L., Kohli, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.038 · Cited by 151
CDK9 Regulates AR Promoter Selectivity and Cell Growth through Serine 81 Phosphorylation
Gordon, V. L., Bhadel, S., Wunderlich, W., Zhang, J., Ficarro, S. B., Mollah, S., Shabanowitz, J., Hunt, D. F., Xénarios, I., Hahn, W. C., et al. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0238 · Cited by 152
Hypermethylation of Genes for Diagnosis and Risk Stratification of Prostate Cancer
Vanaja, D. K., Ehrich, M., van den Boom, D., Cheville, J. C., Karnes, R. J., Tindall, D. J., Cantor, C. R., & Young, C. Y. F. (2009) · Cancer Investigation · doi:10.1080/07357900802620794 · Cited by 137
HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
CHIEN, J. R., Campioni, M., Shridhar, V., & Baldi, A. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909788486704 · Cited by 135
Vainio, P., Gupta, S., Ketola, K., Mirtti, T. K., Mpindi, J.-P., Kohonen, P. J., Fey, V., Perälä, M., Smit, F. P., Verhaegh, G. W. C. T., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.10.002 · Cited by 135
Identification of Key Processes Underlying Cancer Phenotypes Using Biologic Pathway Analysis
Efroni, S., Schaefer, C. F., & Buetow, K. H. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000425 · Cited by 133
Nonparametric Bayesian sparse factor models with application to gene expression modeling
Knowles, D. A., & Ghahramani, Z. (2011) · The Annals of Applied Statistics · doi:10.1214/10-aoas435 · Cited by 132
A Molecular Signature Predictive of Indolent Prostate Cancer
Irshad, S., Bansal, M., Castillo-Martín, M., Zheng, T., Aytés, À., Wenske, S., Magnen, C. L., Guarnieri, P., Sumazin, P., Benson, M. C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006408 · Cited by 148
Wang, J., Place, R. F., Huang, V., Wang, X., Noonan, E. J., Magyar, C. E., Huang, J., & Li, L.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2414 · Cited by 132
Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer
Li, S., Fong, K.-W., Gritsina, G., Zhang, A., Zhao, J. C., Kim, J., Sharp, A., Yuan, W., Aversa, C., Yang, X. J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2812 · Cited by 132
CCR2 expression correlates with prostate cancer progression
Lü, Y., Cai, Z. Y., Xiao, G., Liu, Y., Keller, E. T., Yao, Z., & Zhang, J. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21220 · Cited by 131
Pathway and network analysis in proteomics
Wu, X., Hasan, M. A., & Chen, J. Y. (2014) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2014.05.031 · Cited by 130
Amin, M. B., Lin, D. W., Gore, J. L., Srigley, J. R., Samaratunga, H., Egevad, L., Rubin, M. A., Nacey, J. N., Carter, H. B., Klotz, L. H., et al. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0219-sa · Cited by 127
Telomeres and telomerase in prostate cancer development and therapy
Graham, M. K., & Meeker, A. K. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.104 · Cited by 144
Bostwick, D. G., & Liang Cheng, C. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.04007.x · Cited by 125
Quantitative Proteomic Profiling of Prostate Cancer Reveals a Role for miR-128 in Prostate Cancer
Khan, A. P., Poisson, L., Bhat, V. B., Fermin, D., Zhao, R., Sundaram, S. K., Michailidis, G. C., Nesvizhskii, A. I., Omenn, G. S., Chinnaiyan, A. M., et al. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900159-mcp200 · Cited by 125
Nadiminty, N., Tummala, R., Liu, C., Lou, W., Evans, C. P., & Gao, A. C. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1057 · Cited by 132
Song, Z., Chao, F., Zhuo, Z., Ma, Z., Li, W., & Chen, G. (2019) · Aging · doi:10.18632/aging.102087 · Cited by 124
Bypass Mechanisms of the Androgen Receptor Pathway in Therapy-Resistant Prostate Cancer Cell Models
Marques, R. B., Dits, N. F. J., Erkens‐Schulze, S., van Weerden, W. M., & Jenster, G. W. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013500 · Cited by 127
Zhang, X.-Y., Cowper-Sallari, R., Bailey, S., Moore, J. H., & Lupien, M. (2012) · Genome Research · doi:10.1101/gr.135665.111 · Cited by 138
AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis
Li, N., Xue, W., Yuan, H., Dong, B., Ding, Y., Liu, Y., Jiang, M., Kan, S., Sun, T., Ren, J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91144 · Cited by 120
Metadata
- Authors
- Yu, Y. P., Landsittel, D., Jing, L., Nelson, J., Ren, B., Liu, L., McDonald, C., Thomas, R., Dhir, R., Finkelstein, S., Michalopoulos, G., Becich, M., & Luo, J.-H.
- Affiliations
- University of Pittsburgh (US)
- From the Department of Pathology and Urology, University of Pittsburgh School of Medicine, and Biostatistics Center, University of Pittsburgh Cancer Institute and Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2004-07-15
- Volume
- 22
- Issue
- 14
- Pages
- 2790-2799
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2108426942
- Semantic Scholar
- 8be3bd0e253d2a736b72002f40143dec896e862a
- Cited by
- 758
- References
- 23
- Citations by year
- 2026: 12 · 2025: 9 · 2024: 31 · 2023: 31 · 2022: 20 · 2021: 30 · 2020: 26 · 2019: 29 · 2018: 29 · 2017: 38 · 2016: 24 · 2015: 47 · 2014: 58 · 2013: 41 · 2012: 47
- FWCI
- 10.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (U01CA088110, 1U01 CA 88110-01, R01CA098249)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- prostate cancer, gene expression profiling, tumor aggressiveness, prostate carcinogenesis, gene expression patterns
- MeSH terms
- Adult, Cell Transformation, Neoplastic, Humans, Male, Middle Aged, Neoplasm Invasiveness, Predictive Value of Tests, Prostate, Prostatic Neoplasms, Gene Expression, Disease Progression, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.